High Court Skips Amgen Unit's Arthrex Arguments In IP Case
The U.S. Supreme Court refused Monday to review whether an Amgen Inc. unit's patent on treating inflammatory disorders was improperly struck down, despite arguments that the invalidation was decided by unconstitutionally...To view the full article, register now.
Already a subscriber? Click here to view full article